Compare JOE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | ERAS |
|---|---|---|
| Founded | 1936 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 2002 | 2021 |
| Metric | JOE | ERAS |
|---|---|---|
| Price | $67.45 | $18.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 206.1K | ★ 4.3M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 56.69 | 36.23 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $513,246,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $70.93 | ★ N/A |
| Revenue Growth | ★ 27.44 | N/A |
| 52 Week Low | $46.37 | $1.33 |
| 52 Week High | $73.54 | $24.28 |
| Indicator | JOE | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 71.26 | 51.65 |
| Support Level | $66.12 | $17.63 |
| Resistance Level | $72.64 | $19.96 |
| Average True Range (ATR) | 1.93 | 1.01 |
| MACD | 0.67 | -0.25 |
| Stochastic Oscillator | 99.74 | 41.32 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.